Consensus cbdMD, Inc.

Stocks

YCBD

US12482W4087

Pharmaceuticals

Market Closed - NYSE 16:00:00 2026-09-28 EDT			5-day change	1st Jan Change
0.4635 ^USD	-0.96%		+5.34%	-65.67%

09-02	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI
08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT

Evolution of the Average Target: cbdMD, Inc.

Evolution of the Target Price: cbdMD, Inc.

Changes in Analyst Recommendations: cbdMD, Inc.

451ebbe7b11eb1c.DiUFBw-1JNgUctNjqszyA48kFHRtlcaIlBY0sGLDmxQ.ZH9jf0jWc-hBAaBbn4vAU-R0bhsd3ozCpUFHxlOO3yVkRERFSIVgoTk_lg~8ced607cd7cc07a131df5aa35e05e5d7

Analysts' recommendations: cbdMD, Inc.

08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
23-10-05	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
21-06-18	CbdMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CBDMD, INC.			-	-	-
	ELI LILLY AND COMPANY					+11.99%
	JOHNSON & JOHNSON					+2.47%
	ABBVIE INC.					+5.4%
	ROCHE HOLDING AG					+4.17%
	NOVARTIS AG					+5.45%
	ASTRAZENECA PLC					+27.21%
	AMGEN INC.					-6.12%
	GILEAD SCIENCES, INC.					+5.12%
	NOVO NORDISK A/S					+21.56%
	Average					+8.58%
	Weighted average by Cap.					+8.25%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

HOLD

Number of Analysts

1

Last Close Price

0.4635

Average target price

-

Analyst Consensus Detail

Consensus revision (last 18 months)

Stock Market
Stocks
YCBD Stock
Consensus cbdMD, Inc.

The best tools reserved for subscribers to boost the performance of your investments!